LLLouis Larrouquere

Louis Larrouquere

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Louis Larrouquere has a total of 54 co-authors. Here are the top co-authors by number of shared publications:

  • Alice Bonneville-Levard

    Neuro-Oncology, Department of Oncology, Leon Berard Cancer Centre , Lyon

    2 shared publications
  • Thomas Bachelot

    Département de cancérologie médicale, centre Léon-Bérard, 28, rue Laënnec, 69008 Lyon, France; Centre de recherche en cancérologie de Lyon (UMR Inserm 1052, CNRS 5286, UCBL1, centre Léon-Bérard), Lyon, France

    2 shared publications
  • Alex Hlavaty

    Univ. Grenoble Alpes, CHU Grenoble Alpes, Grenoble, France

    1 shared publication
  • Alexandre Basle

    Départment d’imagerie, Centre Léon Bérard , Lyon

    1 shared publication
  • Alexandre Bellier

    Univ. Grenoble Alpes, CHU Grenoble Alpes, Grenoble, France

    1 shared publication
  • Amelle Mouffak

    Univ. Grenoble Alpes, CHU Grenoble Alpes, Grenoble, France

    1 shared publication

Latest Publications

  • Open Access

    Métastases leptoméningées dans le cancer du sein – État des lieux et perspectives

    by Louis Larrouquere, Emilie Clement, Marie Pierre Sunyach, Axel De Bernardi, Erika Cosset, Thomas Bachelot


  • Open Access

    Feasibility and efficacy of MEMMAT-like regimen in heavily pretreated adult patients with recurrent malignant embryonal brain tumors: A series of 6 cases

    by Aurelien Maureille, Enora Vauleon, David Meyronet, Cécile Faure-Conter, Alexandre Basle, Louis Larrouquere, Anne Pagnier, Marc Barritault, Alice Bonneville-Levard, Pierre Leblond

    Background: The prognosis of adult patients with recurrent malignant embryonal brain tumors remains poor due to the lack of effective and validated treatment. A metronomic and antiangiogenic chemotherapy regimen called MEMMAT was developed in children, with promising results. Additional data on feasibility, tolerance, and efficacy in adults are necessary. Methods: This retrospective observational case series included adult patients with relapsing medulloblastoma (MB) or pineoblastoma (PB) treated with MEMMAT-adapted protocol. Treatment consisted of daily oral thalidomide, fenofibrate, and celecoxib, and alternating 21-day cycles of metronomic etoposide and cyclophosphamide associated with bevacizumab and personalized intraventricular chemotherapy. Results: Four SHH-activated MB and 2 PB were included. Median duration of treatment was 12 months (range 3–21). Significant partial response occurred in 2/4 MB patients and 2/2 PB. The best responses were observed on leptomeningeal lesions. Main grade 3–4 toxicity was neutropenia in all patients (no febrile neutropenia) and lymphopenia in all but one (2 opportunistic infections). Dose adjustments in chemotherapy and thalidomide for hematotoxicity were necessary in all patients within the first 3 months. Cumulative neurotoxicity from thalidomide affected the 4 patients with prolonged treatment (1 grade 3, 3 grade 2). Rechallenge was tried in PB patients and successful (duration: 9 months). Conclusions: MEMMAT is feasible in adult patients and can lead to a significant and sustained response in recurrent malignant embryonal brain tumors. Hematotoxicity is progressive and manageable. The withdrawal of thalidomide and starting dose adjustments on chemotherapy might be discussed.


  • Open Access

    Long-term response to sequential anti-HER2 therapies including trastuzumab-deruxtecan in a patient with HER2-positive metastatic breast cancer with leptomeningeal metastases: a case report and review of the literature

    by Axel de Bernardi, Thomas Bachelot, Louis Larrouquère

    The incidence of leptomeningeal metastases (LM) is increasing among breast cancer patients, but their prognosis remains dismal. Many therapeutic options are now available to treat HER2-positive (HER2+) metastatic breast cancer (MBC) involving the central nervous system (CNS). This case report illustrates a long-lasting response of more than 2 years in a patient with HER2+ MBC with LM after sequential administration of systemic and intrathecal (IT) anti-HER2 therapies and highlights that an appropriate treatment of HER2+ LM can result in durable survival.


  • Open Access

    Intensive pediatric chemotherapy regimen (PNET HR+5) in adult high-risk medulloblastoma and pineoblastoma patients

    by Louis Larrouquere, Christelle Dufour, Cécile Faure-Conter, Claire Alapetite, David Meyronet, Stéphanie Bolle, Alice Bonneville-Levard, Marie-Pierre Sunyach, Valérie Laurence, Didier Frappaz

    Background: High-risk medulloblastoma (HRMB) is rare in adults. The 5-year overall survival rate is less than 60%. We present here a retrospective analysis of adults treated with an intensive pediatric chemo-radiotherapy regimen PNET HR + 5: NCT00936156. Methods: Eighteen patients over the age of 20 (range, 20–33 years) with HRMB (n = 13), pinealoblastoma (n = 4), and central nervous system embryonal tumor (n = 1) were treated with 2 courses of carboplatin-etoposide followed by 2 courses of high-dose thiotepa (HDT) with autologous hematopoietic stem-cell rescue. A craniospinal irradiation (CSI; 36 Gy craniospinal axis then a boost of 18 Gy to the primary tumor site) was then initiated within 150 days of surgery, completed with 6 cycles of temozolomide; the axis irradiation was not mandatory for non-metastatic pinealoblastoma. Results: We observed no progression under chemotherapy and no toxic death. Four patients received only 1 HDT. Two non-metastatic pinaloblastomas received only focal irradiation. One medulloblastoma received only 25 Gy on the axis. 56% (10/18) received 6 cycles of temozolomide. No long-term toxicity was recorded. The median time between surgery and CSI was 175 days (range, 115–250). With a median follow-up of 6.0 years (range, 2.6–9), the progression-free survival and overall survival rates for medulloblastoma were respectively 65% (95% CI: 31%–86%) and 76% (95% CI: 42%–91%) at 5 years. Conclusions: The PNET HR + 5 regimen showed promising results in an adult population, with a meaningful improvement in progression-free survival and overall survival in patients with HRMB.

  • Open Access

    Preclinical Evaluation of Sodium Selenite in Mice: Toxicological and Tumor Regression Studies after Striatum Implantation of Human Glioblastoma Stem Cells

    by Louis Larrouquère, Sylvie Berthier, Benoit Chovelon, Catherine Garrel, Véronique Vacchina, Hugues Paucot, Jean Boutonnat, Patrice Faure, Florence Hazane-Puch

    Glioblastoma (GBM) is the most aggressive malignant glioma, with a very poor prognosis; as such, efforts to explore new treatments and GBM’s etiology are a priority. We previously described human GBM cells (R2J-GS) as exhibiting the properties of cancer stem cells (growing in serum-free medium and proliferating into nude mice when orthotopically grafted). Sodium selenite (SS)—an in vitro attractive agent for cancer therapy against GBM—was evaluated in R2J-GS cells. To go further, we launched a preclinical study: SS was given orally, in an escalation-dose study (2.25 to 10.125 mg/kg/day, 5 days on, 2 days off, and 5 days on), to evaluate (1) the absorption of selenium in plasma and organs (brain, kidney, liver, and lung) and (2) the SS toxicity. A 6.75 mg/kg SS dose was chosen to perform a tumor regression assay, followed by MRI, in R2J-GS cells orthotopically implanted in nude mice, as this dose was nontoxic and increased brain selenium concentration. A group receiving TMZ (5 mg/kg) was led in parallel. Although not reaching statistical significance, the group of mice treated with SS showed a slower tumor growth vs. the control group (p = 0.08). No difference was observed between the TMZ and control groups. We provide new insights of the mechanisms of SS and its possible use in chemotherapy.


  • Genesis of an emergency public drug information website by the French Society of Pharmacology and Therapeutics during the COVID‐19 pandemic

    by Louis Larrouquere, Manon Gabin, Emmanuelle Poingt, Amelle Mouffak, Alex Hlavaty, Marion Lepelley, Charles Khouri, Alexandre Bellier, Joachim Alexandre, Pierrick Bedouch, et al.

    On March 16, 2020, the French Society of Pharmacology and Therapeutics put online a national Question and Answer (Q&A) website, https://sfpt-fr.org/covid19 on the proper use of drugs during the COVID‐19 pandemic. The working group “Drugs and COVID‐19” was composed of a scientific council, an editorial team and experts in the field. The first questions were posted online during the first evening of home‐confinement in France, March 17, 2020. Six weeks later, 140 Q&As have been posted. Questions on the controversial use of hydroxychloroquine and to a lesser extent concerning azithromycin have been the most consulted Q&As. Q&As has been consulted 226,014 times in 41 days. This large visibility was obtained through an early communication on Twitter, Facebook, traditional print and web media. In addition, an early communication through the French Ministry of Health and the French National Agency for Medicines and Health Products Safety ANSM had a large impact in terms of daily number of views. There is a pressing need to sustain a public drug information service combining the expertise of scholarly pharmacology societies, pharmacovigilance network, and the Ministry of Health to quickly provide understandable, clear, expert answers to the general population’s concerns regarding COVID‐19 and drug use and to counter fake news.